Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: An integrated analysis of three 12-week studies

CNS Drugs

Volumn 26, Issue 9, 2012, Pages 773-780

  VanMeter, Susan A ^a   Kavanagh, Sarah T ^a   Warren, Samantha ^a   Barrett, Ronald W ^b  

^a GLAXOSMITHKLINE   (United States)

^b XenoPort Inc   (United States)

Author keywords

Gabapentin enacarbil; Restless legs syndrome

Indexed keywords

GABAPENTIN ENACARBIL; PLACEBO;

ADULT; CLINICAL GLOBAL IMPRESSION SCALE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOOD; HEADACHE; HUMAN; INCIDENCE; INTERNATIONAL RESTLESS LEGS SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; RHINOPHARYNGITIS; RISK; SOMNOLENCE; STATISTICAL SIGNIFICANCE;

CARBAMATES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT SATISFACTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865209161     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634870-000000000-00000     Document Type: Review

References (14)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-19
2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-92
3. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-46
4. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004; 311: 324-33
5. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004; 311: 315-23
6. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokine-tics of XP13512, a novel transported prodrug of gaba-pentin. J Clin Pharmacol 2008; 48: 1378-88
7. Horizant®: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us-horizant. pdf [Accessed 2012 Jan]
8. Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011; 7: 282-92
9. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, two-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009; 32: 311-20
10. Lal R, Ellenbogan AL, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. In press
11. Bogan RK, Cramer Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010; 85: 512-21
12. Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011; 34: 8-16
13. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled trial of XP13512/GSK 1838262 in patients with RLS. Neurology 2009; 72: 439-46
14. Kushida CA, Walters AS, Becker P, et al. A random-ized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32: 159-68